Development of new diagnostic assays for improved precision cancer medicine in glioma and acute leukemia
| Reference number | |
| Coordinator | Lunds universitet - Lunds Universitet Inst f kulturvetenskaper |
| Funding from Vinnova | SEK 3 599 565 |
| Project duration | August 2020 - February 2023 |
| Status | Completed |
| Venture | Bilateral call for proposals with China |
| Call | Research, development and innovation in the fields of life science, traffic safety and applied ICT - China collaboration |
Important results from the project
The overall aim of the project has been to improve diagnostics and treatment of cancer based on measurements of gene expression and methylation patterns, especially in blood cancers (acute leukemias) and brain tumors (gliomas). All milestones and goals were achieved, which will facilitate improved future clinical diagnostics of the investigated cancers.
Expected long term effects
Within the project, protocols, methods and innovative software have been developed, enabling improved classification of blood cancer and brain tumors based on gene expression patterns and methylation patterns, respectively. The software of participating SME has been prepared to meet current (CE-IVD) regulatory requirements. The project is expected to lead to improved future precision diagnostics of cancer, has resulted in several scientific publications, and in lasting collaborations.
Approach and implementation
The project has been carried out as four work packages in collaboration between three partners from Sweden and four from China, with a participating SME in each country. After an initial delay of 6 months, the project has met all milestones and the overall goal. Regular digital meetings have been held to follow the progress of the work and report the results, also in the form of scientific publications. The fruitful collaboration between the parties will continue beyond the current project period.